Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.

about

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q47393206

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Hematological adverse effects ...... atic review and meta-analysis.

@en

Hematological adverse effects ...... atic review and meta-analysis.

@nl

type

Item

label

Hematological adverse effects ...... atic review and meta-analysis.

@en

Hematological adverse effects ...... atic review and meta-analysis.

@nl

prefLabel

Hematological adverse effects ...... atic review and meta-analysis.

@en

Hematological adverse effects ...... atic review and meta-analysis.

@nl

P1476

Hematological adverse effects ...... atic review and meta-analysis.

@en

P2093

Kyrillus S Shohdy

http://www.w3.org/2001/XMLSchema#string

Loay Kassem

http://www.w3.org/2001/XMLSchema#string

Omar Abdel-Rahman

http://www.w3.org/2001/XMLSchema#string

Shaimaa Lasheen

http://www.w3.org/2001/XMLSchema#string

Thomas Bachelot

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle, CDKs and cancer: a changing paradigm

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Meta-analysis in clinical trials

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

The history and future of targeting cyclin-dependent kinases in cancer therapy.

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

P2888

s12282-017-0818-4

P304

17-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S12282-017-0818-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29147869

http://www.w3.org/2001/XMLSchema#string